Brief: Apogee Therapeutics Announces First Participants Dosed In Phase 1 Clinical Trial Of Apg990
19/08/2024 12:44
Aug 19 (Reuters) - Apogee Therapeutics Inc APGE.O :
* APOGEE THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED IN
PHASE
1 CLINICAL TRIAL OF APG990, ITS NOVEL HALF-LIFE EXTENDED OX40L
ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS AND OTHER
INFLAMMATORY DISEASES
* APOGEE THERAPEUTICS INC - EXPECTS APG990 INTERIM DATA IN
2025
* APOGEE THERAPEUTICS INC - TO INITIATE APG777 AND APG990
TRIAL IN
2025
Source text for Eikon: ID:nGNX3RR7bJ
Further company coverage: APGE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)